IS7798A - Efnasambönd, lyfjablöndur og aðferðir - Google Patents

Efnasambönd, lyfjablöndur og aðferðir

Info

Publication number
IS7798A
IS7798A IS7798A IS7798A IS7798A IS 7798 A IS7798 A IS 7798A IS 7798 A IS7798 A IS 7798A IS 7798 A IS7798 A IS 7798A IS 7798 A IS7798 A IS 7798A
Authority
IS
Iceland
Prior art keywords
compounds
methods
pharmaceutical preparations
preparations
pharmaceutical
Prior art date
Application number
IS7798A
Other languages
English (en)
Inventor
Bergnes Gustave
Qian Xianping
J. Morgans David Jr.
David Knight Steven
Dhanak Dashyant
Original Assignee
Cytokinetics, Incorporated
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics, Incorporated, Smithkline Beecham Corporation filed Critical Cytokinetics, Incorporated
Publication of IS7798A publication Critical patent/IS7798A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
IS7798A 2002-10-11 2005-04-11 Efnasambönd, lyfjablöndur og aðferðir IS7798A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41788902P 2002-10-11 2002-10-11
PCT/US2003/031413 WO2004032840A2 (en) 2002-10-11 2003-10-02 Compounds, compositions, and methods

Publications (1)

Publication Number Publication Date
IS7798A true IS7798A (is) 2005-04-11

Family

ID=32094113

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7798A IS7798A (is) 2002-10-11 2005-04-11 Efnasambönd, lyfjablöndur og aðferðir

Country Status (19)

Country Link
US (1) US7476743B2 (is)
EP (1) EP1558588A4 (is)
JP (1) JP2006502219A (is)
KR (1) KR20050075356A (is)
CN (1) CN1726198A (is)
AR (1) AR044193A1 (is)
AU (1) AU2003282665A1 (is)
BR (1) BR0315247A (is)
CA (1) CA2501938A1 (is)
IL (1) IL167936A0 (is)
IS (1) IS7798A (is)
MX (1) MXPA05003830A (is)
NO (1) NO20052267L (is)
NZ (1) NZ539643A (is)
PL (1) PL375889A1 (is)
RU (1) RU2005114491A (is)
TW (1) TW200418818A (is)
WO (1) WO2004032840A2 (is)
ZA (1) ZA200503733B (is)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101170925B1 (ko) * 2004-06-18 2012-08-07 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 암 치료용 키네신 방추 단백질 (ｋｓｐ) 억제제로서의ｎ-(1-(1-벤질-4-페닐-1ｈ-이미다졸-2-일)-2,2-디메틸프로필)벤자미드 유도체 및 관련 화합물
KR20070046176A (ko) 2004-08-18 2007-05-02 아스트라제네카 아베 특정 융합 피리미돈의 거울상이성질체 및 이의 암 치료 및예방에 있어서의 용도
DE102006023337A1 (de) * 2006-05-18 2007-11-22 Merck Patent Gmbh Triazolderivate II
JP5343363B2 (ja) * 2008-01-31 2013-11-13 アイシン精機株式会社 シートクッション調整装置
CN101643451B (zh) * 2008-08-07 2013-03-06 浙江海正药业股份有限公司 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
CA2794406A1 (en) 2010-04-15 2011-10-20 Novartis Ag Triazole compounds as ksp inhibitors
WO2012095691A1 (en) * 2011-01-15 2012-07-19 Jubilant Life Sciences Ltd. An improved process for producing aminopyridines
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
WO2014099503A1 (en) 2012-12-20 2014-06-26 Inception 2, Inc. Triazolone compounds and uses thereof
PE20160880A1 (es) 2013-09-06 2016-09-22 Inception 2 Inc Compuestos de triazolona y usos de los mismos
CN114917361A (zh) * 2015-06-22 2022-08-19 拜耳医药股份有限公司 具有酶可裂解基团的抗体药物缀合物（adc）和抗体前药缀合物（apdc）
TW201722958A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產（第二）有限公司 化學化合物
PE20191235A1 (es) 2016-12-21 2019-09-11 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente
WO2023192499A1 (en) * 2022-03-30 2023-10-05 Primefour Therapeutics, Inc. Nucleosides for treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE793532A (fr) * 1971-12-29 1973-06-29 Upjohn Co Nouvelles 1,2,4-triazol-3-ones et leur preparation
US3748339A (en) 1972-05-05 1973-07-24 Upjohn Co 2-(3-(1-(dimethylamino)alkyl)-1,5-dihydro-5-oxo - 1 - substituted-4h-1,2,4-triazol-4-yl)benzophenone and process
DK501077A (da) 1976-11-17 1978-05-18 Montedison Spa Nye phosphorsyreestere afledt af 1,2,4-triazol med insekticid nematodicid og acaricid virkning og fremgangsmaade til fremstilling deraf
IT1068010B (it) * 1976-11-17 1985-03-21 Montedison Spa Nuovi esteri fosforici derivati dall' 1-2-4 triazolo ad azione insetticida,nematocida e acaricida e loro preparazione
US4487773A (en) 1981-03-16 1984-12-11 Mead Johnson & Company 1,2,4-Triazol-3-one antidepressants
US5250558A (en) * 1992-01-28 1993-10-05 Merck & Co., Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as neurotensin antagonists used to treat psychosis
GB9211193D0 (en) * 1992-05-27 1992-07-08 Merck Sharp & Dohme Therapeutic agents
IL106142A (en) * 1992-06-29 1997-03-18 Merck & Co Inc Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
JP2002534955A (ja) * 1995-10-18 2002-10-15 メルク エンド カンパニー インコーポレーテッド シクロペンチルタキキニン受容体アンタゴニスト
JP2002234874A (ja) * 2000-09-26 2002-08-23 Tanabe Seiyaku Co Ltd ５−フェニルベンジルアミン誘導体、その製法及びその合成中間体
CA2425908A1 (en) * 2000-10-26 2002-05-02 Merck & Co., Inc. Mammalian metabolites of a tachykinin receptor antagonist
ATE446094T1 (de) * 2002-06-14 2009-11-15 Merck & Co Inc Mitotische kinesin-hemmer

Also Published As

Publication number Publication date
WO2004032840A3 (en) 2004-10-14
EP1558588A4 (en) 2006-11-02
NO20052267L (no) 2005-05-31
US7476743B2 (en) 2009-01-13
US20060189671A1 (en) 2006-08-24
JP2006502219A (ja) 2006-01-19
PL375889A1 (en) 2005-12-12
KR20050075356A (ko) 2005-07-20
ZA200503733B (en) 2006-02-22
EP1558588A2 (en) 2005-08-03
AU2003282665A1 (en) 2004-05-04
CN1726198A (zh) 2006-01-25
RU2005114491A (ru) 2006-02-10
NZ539643A (en) 2006-11-30
MXPA05003830A (es) 2005-06-23
IL167936A0 (en) 2009-02-11
WO2004032840A2 (en) 2004-04-22
BR0315247A (pt) 2005-08-30
CA2501938A1 (en) 2004-04-22
AR044193A1 (es) 2005-09-07
TW200418818A (en) 2004-10-01

Similar Documents

Publication Publication Date Title
IS7798A (is) Efnasambönd, lyfjablöndur og aðferðir
DK1511734T3 (da) Forbindelser, præparater og fremgangsmåder
NO20052855D0 (no) Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav.
NO20053817D0 (no) Preparater og fremgangsmater for antiviral kombinasjonsterapi.
NO20044192L (no) 17alfa-alkyl-17beta-oksy-ostratriener og farmasoytiske preparater
NO20033556D0 (no) Farmasöytiske preparater
IS8153A (is) Ónæmisbælandi efnasambönd og efnablöndur
DK1400518T3 (da) Heterocycliske forbindelser og lægemidler
NO20042084L (no) 6-hydroksyisoflavoner, derivater og legemidler som omfatter disse
NO20043839L (no) Havbunnsbasert intervensjonssystem, fremgangsmate for og komponeter i dette
PT1501534E (pt) Formulacoes farmaceuticas
IS7946A (is) Lyf
NO20052285D0 (no) Faste, partikkelformige, antifungale preparater for farmasoytisk anvendelse
DK1575618T3 (da) Dispergerbare farmaceutiske kombinationer
IS7549A (is) Olíuleysanlegar efnablöndur
IS8422A (is) Bensímídasólafleiður, efnablöndur sem innihalda þær, framleiðsla þeirra og notkun þeirra
NO20051983D0 (no) 3-fenyl-substituert pyridoindolon, fremstilling derav og terapeutisk anvendelse derav.
IS8219A (is) Bensímídasólafleiður, efnablöndur sem innihalda þær, framleiðsla þeirra og notkun
NO20054674L (no) Benzotiazolderivatforbindelser, preperater og anvendelser
NO20053809D0 (no) Diarylmetylindenpiperidinderivater,fremgangsmate for fremstilling derav, og anvendelse derav
NO20035315D0 (no) Farmasöytiske kombinasjoner
DK1513835T3 (da) Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
DK1590321T3 (da) Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
DK1560826T3 (da) Pyridopyrimidinonderivater, fremgangsmåde til fremstiling heraf og farmaceutiske sammensætninger indeholdende disse
DK1417189T3 (da) Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf